Abstract Thromboxane A 2 (TxA 2 ), the principle product of platelet COX-1-dependent arachidonic acid metabolism, directs multiple pro-atherogenic processes via its receptor, TP. Oxidative challenge offsets TP degradation, a key component in limiting TxA 2 ʼs actions. Following TP activation, we observed cellular reactive oxygen species (ROS) generation coincident with increased TP expression. We examined the link between TP-evoked ROS and TP regulation. TP expression was augmented in TPa-transfected cells treated with a
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analog [1S-1a,2b(5Z),3a(1E,3R*),4a]]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid (IBOP)
. This was reduced with a cellular antioxidant, N-acetyl cysteine, or two distinct NADPH oxidase inhibitors, diphenyleneiodonium and apocynin. Homologous upregulation of the native TP was also reduced in apocynintreated aortic smooth muscle cells (ASMCs) and was absent in ASMCs lacking an NADPH oxidase subunit (p47 2/2 ). TP transcription was not increased in IBOP-treated cells, indicating a posttranscriptional mechanism. IBOP induced translocation of TPa to the Golgi and reduced degradation of the immature form of the receptor. These data are consistent with a ROS-dependent mechanism whereby TP activation enhanced TP stability early in posttranscriptional biogenesis. Given the significant role played by TP and ROS in perturbed cardiovascular function, the convergence of TP on ROSgenerating pathways for regulation of TxA 2 -dependent events may be critical for cardiovascular disease. Thromboxane A 2 (TxA 2 ), derived predominantly from platelet COX-1-dependent metabolism of arachidonic acid, is integral to cardiovascular disease (CVD). TxA 2 directs multiple processes, including vasoconstriction, platelet aggregation, and smooth muscle cell (SMC) proliferation via its cell surface G-protein-coupled receptor (GPCR), the TP (1) . Antagonism or deletion of TP retarded atherogenesis (2, 3) and blunted the proliferative response to vascular injury (4) or remodeling (5) in mice.
Regulation of TP expression, which is augmented in human CVD (6, 7) , has received less attention compared with the coincident increase in the biosynthesis of its ligand, TxA 2 (3, 8) . Indeed, despite the diversity of platelet agonists, the cardioprotective effects of aspirin are realized through irreversible inhibition of platelet COX-1-derived TxA 2 (9) . Conversely, the unrestricted TxA 2 generation, with concomitant depression of its opposing mediator prostacyclin, associated with selective COX-2 inhibitors, is the leading explanation for the cardiovascular hazard associated with that class of drugs (10) , underscoring the central role played by this eicosanoid during cardiovascular function and disease. However, a TP antagonist was more effective in offsetting lesion formation compared with inhibitors of TxA 2 synthesis in atherosclerotic mice (2, 3) , warranting examination of receptor-specific events in CVD.
In addition to their role as signaling intermediates (11), reactive oxygen species (ROS) may regulate GPCR function and expression. Exogenous hydrogen peroxide (H 2 O 2 ) promoted desensitization of the dopamine D1 receptor (12) . In contrast, the sphingnosine 1-phosphate S1P 1 receptor (13) and the TP (14) are posttranslationally upregulated by H 2 O 2 . These observations suggest a role for intracellular ROS in controlling protein expression and represent a potential mechanism for regulating TP expression. This currently untested hypothesis is especially interesting given that NADPH oxidase, a major source of vascular ROS (15) , is an effector for TP (16, 17) , while antagonism of the TP offset NADPH oxidase expression and renal oxidant stress in diabetic hyperlipidemic mice (18) . Indeed, similar to other vasoactive mediators (15) , NADPH oxidase-derived cellular ROS may be integral to TxA 2 ʼs cardiovascular actions (16, 17) .
We examined the role of TP-generated cellular oxidants in regulation of TP expression. We report a novel feed-forward loop in which TP activation promotes upregulation of TP expression through a ROS-dependent mechanism of enhanced receptor stability early in biogenesis.
METHODS

Cell Culture and Transfection
Hemagglutinin (HA) epitope tagged human (h) TPa was generated as described (19) . hTPa, triple (3x) HA-tagged, was from the Missouri S and T cDNA Resource Center. HEK 293 cells (ATCC, Rockville, MD) and human (h) aortic (A) SMCs (Biowhittaker, MD) were maintained as described (20) . SMCs were isolated from wild-type or p47 2/2 mouse aortic explants as described (19) . HEK 293 cells were transfected with HAhTPa, for stable expression (hereafter termed TPa-HEK), or transiently with 3xHAhTPa (hereafter termed 3xHAhTPa-HEK) as described (21) . Experiments were carried out 48 h after transfection.
Radioligand binding
TPa-HEK were scraped into buffer (10 mM HEPES, pH 7.4, 1 mM EDTA, and protease inhibitors) and homogenized (TissueLyser™; Qiagen; 2 x 3 min at 30 MHz). Intact cells and nuclei were removed (2 x 1,800 g, 10 min). The crude membrane fraction was isolated from the resulting supernatant by ultracentrifugation (100,000 g, 1 h at 4°C) and resuspended in buffer. TP radiolabeled using a saturating concentration (150 nM) of the TP antagonist 3 H-SQ 29548 (Perkin-Elmer, MA) as described (21) . For saturation binding, increasing concentrations of 3 H-SQ 29548 were used. Nonspecific binding was quantified using excess unlabeled SQ 29548.
To measure binding to intact human aortic smooth muscle cells (hASMCs), cells were detached (0.02% EDTA) and resuspended in HBSS containing 0.2% BSA. Cells (?20,000) were incubated with a saturating concentration of 3 H-SQ 29548 (250 nM) overnight at 4°C. The reaction was stopped with ice-cold HBSS/BSA and GF/C filter (Whatmann) filtration. Radioactivity associated with washed filters was quantified.
Measurement of ROS
Intracellular ROs were measured by carboxy methyl dichloroflourescein fluorescence. Cells were seeded into 96-well plates or coverslips, grown for 24 h, and loaded with 10 mM carboxy methyl dichloroflourescein in HBSS for 1 h at 37°C. Cells were washed and fluorescence measurements taken, before and after [1S-1a,2b(5Z),3a(1E,3R*),4a]]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid (IBOP) treatment, using a Victor spectrophotometer (Perkin-Elmer), with excitation and emission at 485 and 535 nm, respectively. Images were captured with a Hamamatsu camera (Hamamatsu City, Japan) using Metamorph software V6.0 (Universal Imaging Corporation, PA) on an Inverted Olympus IX70 microscope (Tokyo, Japan).
Western blotting
Whole-cell lysates were resolved (NuPAGE; Invitrogen, CA). HA-tagged or native TP receptors were visualized with anti-HA (Covance; 1:1,000 dilution) or anti-TP (Cayman Chemicals, MI; 1:100) as previously described (19) .
Quantitative real-time PCR
Cells, in 12-well (TPa-HEK) or 6-well (hASMC) dishes, were treated with IBOP. Total RNA was extracted (RNeasy™; Qiagen, CA), reverse transcribed into cDNA (TaqMan™ reverse transcriptase; Applied Biosystems, CA), and TP mRNA quantified by real-time PCR analysis. Primers and probes were from Ambion, CA (Hs00169054_m1). mRNA levels were normalized by subtracting the C t for b-actin or 18S from the C t for TP, producing a DC t value. The DC t was compared with control using the relative quantitation 2 -( DCt ) method (22) to determine fold change.
Membrane fractionation
TPa-HEK were scraped into buffer (10 mM HEPES, pH 7.4, 1 mM EDTA, 0.25 M sucrose, and protease inhibitors) and homogenized (TissueLyser™; Qiagen; 2 x 3 min at 30 MHz). Intact cells and nuclei were removed (2 x 1,800 g, 10 min). The membrane fraction was isolated by ultracentrifugation (65,000 g, 1 h at 4°C) and resuspended in buffer.
Discontinuous density gradients (2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, and 30%) were prepared using Optiprep™ (Axis-Shield, Norway) according to the manufacturerʼs instructions. Membrane homogenates were loaded onto the gradient and centrifuged (97,000 g for 2.5 h at 4°C). Fractions (1 ml) were collected from the bottom of the tube. The distribution of 3xHAhTPa, calnexin [endoplasmic reticulum (ER)], and golgin-97 (Golgi) was determined by immunoblotting.
Immunofluorescence microscopy 3xHAhTPa-HEK were fixed (4% paraformaldehyde, 30 min, 4°C) and permeabilized (0.1% Triton X-100, 10 min, room temperature). Slides were blocked in PBS containing 5% goat serum and 2% BSA. 3xHAhTPa and Golgin-97 were stained with rat anti-HA (1:500 dilution; Roche Biochemicals, IN) and mouse anti-human golgin-97 (1:200 dilution; Invitrogen) overnight at 4°C. Staining was visualized with Alexi-Fluor 555-labeled anti-rat and Alexi-Fluor 488-labeled anti-mouse (1:1,000 dilution; Invitrogen) for 30 min using an Olympus AX60 microscope.
Statistical analysis
Data were analyzed using Graphpad Prism software. Comparisons were made using a one-sample t-test or by ANOVA, with suitable post hoc multiple comparison testing as appropriate.
RESULTS
TP is coupled to ROS generation
We first confirmed intracellular ROS generation following TP activation. ROS generation was increased in human (h; 
Homologous regulation of TP expression
Oxidative challenge of cells with H 2 O 2 increased TP expression (14) . We considered whether TP expression was similarly enhanced by ROS generated as part of the TP signaling cascade. This concept deviates from the classical notion of GPCR regulation, in which the activated receptor becomes downregulated (23) , and may be highly relevant to increased TP responsiveness in settings of platelet activation, when biosynthesis of TxA 2 is markedly increased (24, 25) . HEK 293 cells stably expressing HAhTPa (TPa-HEK) were treated for 12 h with increasing concentrations of either IBOP, a TxA 2 analog, or iPE 2 III, a free-radical generated arachidonic acid metabolite that activates the TP in vitro (19) and in vivo (26) . TP expression was determined by Western blot analysis. Similar to other GPCRs, differential glycosylation of the TPa (27) gives rise to two major species: the mature, fully glycosylated receptor appears as a broad complex species from 45-60 kDa, while the immature unglycosylated form appears at 39 kDa. These multiple bands were not due to nonspecific antibody binding because neither the mature nor immature TPa species were evident in Western blots of untransfected wild-type HEK cells ( Fig. 2A, left panel) . Treatment with IBOP ( Fig. 2A, C) or iPE 2 III (Fig. 2B, D) increased expression of both the forms of TPa in a concentration-dependent manner. Maximum induction was evident following treatment with 10-100 nM IBOP (2.63 6 0.52-fold over basal; P , 0.05, n 5 5), consistent with the dose response for TP signaling in these cells (19) . A higher concentration of iPE 2 III (500 nM) was required for TP upregulation (1.7 6 0.21-fold over basal; P , 0.05, n 5 3), consistent with its lower affinity for the receptor (19, 26) . TP upregulation was time dependent, with increased expression observed within 6 h (3.03 6 0.68-fold over basal; P , 0.05, n 5 3; Fig. 2E ). Pretreatment with the TP antagonist SQ 29548 inhibited IBOP-induced TP upregulation (Fig. 2F) .
Increased TP expression in IBOP-treated TPa-HEK was confirmed by radioligand binding of 3 H-SQ 29548 to crude cell membrane (Fig. 3A) . The saturation binding isotherm showed a ?40% increase in the Bmax (P , 0.05, n 5 5), without alteration of the dissociation constant (?70 nM; Fig. 3B ), following IBOP treatment. Importantly, increased TP expression following TP activation was not restricted to HEK 293 cells: IBOP (100 nM) increased expression of the native TP in both human, as assessed by binding of 3 H-SQ 29548 to intact cells (2.6 6 0.5-fold over basal; P , 0.05, n 5 3), and mASMC (see Fig. 6 ).
In our HEK 293 cell model, TPa expression is under control of the constitutive cytomegalovirus promoter, making it unlikely that transcriptional changes contributed to TP expression. Indeed, we observed no significant increase in TP mRNA levels in TPa-HEK cells treated with IBOP for 6 h (Fig. 4A ) or 12 h (data not shown). Similarly, we observed no increase in TP mRNA in hASMC treated with IBOP (100 nM) for 12 h or 1mM for up to 24 h (Fig.  4B, C) . These data argue against contribution of a gene transcriptional event to ROS-dependent upregulation of TP expression.
The role of ROS in homologous regulation of TP expression
We next examined whether a redox-dependent mechanism was involved in upregulation of the activated TP. Pretreatment of TPa-HEK with a cell-permeable antioxidant, n-acetyl-cysteine (NAC; 20 mM), abrogated the IBOPinduced (Fig. 5A, B) and iPE 2 III-induced (data not shown) increase in TPa expression, implicating intracellular ROS generation in TP-dependent TP upregulation. Similarly, DPI or apocynin significantly inhibited IBOPinduced TP upregulation in TPa-HEK (Fig. 5A-D) or ASMC (Fig. 6A, B) . Furthermore, IBOP-induced TP upregulation in mASMC was abolished in p47 2/2 mASMC (Fig. 6C, D) . These results indicate that ROS, generated via TP-dependent Fig. 1 . TP-mediated ROS generation. hASMC were treated with IBOP for 3 h (A) or pretreated with NADPH oxidase inhibitors (B) (DPI, 10 mM, or apocynin, 100 mM) for 30 min prior to IBOP (100 nM; 3 h). C: mASMC from wild-type (WT) mice or p47 2/2 mice were treated with IBOP (1 mM) for 3 h. ROS generation was assessed by fluorescent spectrophotometry or microscopy. Data in A and B are fold over basal 6 SE (n 5 3). *** P , 0.001 with reference to (w.r.t.) control. Data in C are a representative experiment that was repeated with similar results.
activation of an NADPH oxidase, underlies TP-dependent increase TP expression.
TP activation induces translocation of TP from the ER to the Golgi
Following synthesis in the ER, correctly folded GPCRs traffic to the Golgi and on to the plasma membrane in their mature form. Posttranslational modifications that occur during this process include glycosylation of the immature receptor, a step that is essential for ER export, and membrane localization of the mature TP (27) . The presence of an intracellular receptor reserve has been reported for some GPCRs, including the TP (14) and thrombin receptors (28) . Exogenous H 2 O 2 facilitated TP mobilization from the ER to the Golgi (14) . We examined whether mobilization of the TP along its biogenic pathways coincided with its upregulation via the TP-derived intracellular ROS pathway. Cell lysates were prepared from TPa-HEK cells, treated (100 nM IBOP; 3 h), and fractionated on discontinuous density gradients optimized for resolution of ER and Golgi membrane fractions (29) . In untreated cells, the majority of HAhTPa resided in the heavier fractions (Fig. 7A, fractions 3-8) and colocalized with the ER marker calnexin; little HAhTPa was present in lighter fractions that costained for the Golgi marker, golgin-97. IBOP treatment shifted this distribution, with increased proportion of HAhTPa found in the Golgi fractions (Fig. 7B, fractions  10-12) . Similarly, prominent colocalization of HAhTPa with golgin-97 was evident in IBOP-treated cells (Fig. 7C) . These data strongly support the concept that activation of the TP facilitates its translocation from the ER to the Golgi along the receptorʼs biogenic pathway. . C-F are mean fold over basal expression of the mature TP 6 SEM from densitometric analysis normalized to b-actin (n 5 3-5). * P , 0.05, ** P , 0.005, and *** P , 0.001 w.r.t. control unless otherwise indicated.
Homologous stabilization of TPa
Degradation of TPa was slowed substantially in cells treated with exogenous H 2 O 2 (14) . We examined whether the TP-ROS-TP feed-forward cycle involved such a posttranslational mechanism of receptor stabilization. HEK 293 cells, transiently transfected with 3xHahTPa, were pretreated with or without IBOP for 1 h before treatment with cycloheximide, to inhibit de novo protein synthesis and unmask receptor degradation. Conventional pulsechase methods, which require metabolic labeling with 35 S-methionine/cysteine, were not successful, probably because of the small number of these residues in the hTP (data not shown). Therefore, we examined the mature glycosylated, and immature unglycosylated, form of the TP by Western blot. In control cells, levels of the mature and immature TPa were significantly reduced, following cyclohexamide treatment, reflecting degradation. Following pretreatment with IBOP (100 nM, 1 h), degradation of mature TP was unchanged (Fig. 8B) . In contrast, degradation of the immature TP form was significantly offset (Fig. 8C ) with sustained upregulation despite the presence of cycloheximide. These data are consistent with IBOP-induced stabilization of the TP, early in the receptorʼs posttranslational processing. This IBOP-induced early stabilization event was reduced in cells treated with DPI (Fig. 9C) ; in the presence of cyclohexamide, the immature TP band was significantly degraded in cells pretreated with DPI prior to addition of IBOP. These data implicate the TP-ROS signaling pathway in promoting TP biogenesis.
DISCUSSION
Oxidative stress and TxA 2 are established mediators of CVD that contribute to vascular injury (4), atherosclerotic lesion formation, and plaque destabilization (3). Our study confirms that, similar to other vasoactive mediators, such as thrombin (30) and angiotensin II (31), TxA 2 activates NADPH oxidases (16) . However, the relevance of TP-induced ROS generation in mediating the physiological and pathophysiological actions of TxA 2 has not been elucidated. Application of exogenous H 2 O 2 promotes stabilization of the TP in transfected cells (14) , suggesting a role for ROS in regulating TP responsiveness. This study set out to determine if endogenous ROS, generated as signaling intermediates secondary to TP activation, could stabilize TP and, consequently, augment the receptorʼs expression. This hypothesis is a departure from the classical understanding of GPCR regulation in which the activated GPCR is downregulated. Two isoforms of the hTP have been described (32) . We concentrated on the more ubiquitous TPa (33) .
TPa was significantly upregulated, in a time-and concentration-dependent manner following treatment with the TP agonist IBOP, in both transiently and stably transfected HEK 293 cells. This reflected an increase in the receptor Bmax, with no significant change in the dissociation constant for binding, indicating that activation of the TPa produced an increase in functional receptor capable of binding agonist. We did not, however, examine whether TPa signaling was similarly augmented because of the confounding issues of receptor activation, desensitization, and internalization (20, 34) , during the continued presence of agonist. Indeed, Western blot does not discriminate between receptor that is available for ligand binding at the plasma membrane versus receptor that is trafficking to or from the membrane. This may explain the apparent discrepancy between the levels of TPa quantified by Western blot (?2-to 3-fold increase) versus radioligand binding (?40% increase) in TPa-HEK. Importantly, we observed a similar upregulation response of the native TP in two ASMC models (human and mouse), arguing against experimental artifacts due to TPa overexpression. The consistent increase in high-affinity membrane-associated TPa, particularly the 2-fold increase observed in whole-cell binding of SQ 29548 to hASMC, strongly suggests an upregulation of functional receptor at the cell surface in IBOP-treated cells. This is a remarkable finding, given our previous report that exposure to TxA 2 analogs, for a shorter time period (2 h), results in TP internalization and that the internalized receptor is not recycled to the plasma membrane (20) . Indeed, these data suggest a distinct feed-forward pathway for upregulation of the homologously activated TP that predominates during continual agonist activation. Such continual activation would be expected in many disease settings, including syndromes of platelet activation and inflammation.
Given the sensitivity of TP expression to exogenous H 2 O 2 (14), we considered whether endogenous ROS generation in response to TP activation can drive TP expression. Pretreatment of TPa-HEK cells with the cell-permeable antioxidant NAC inhibited homologous TP upregulation, consistent with a ROS-dependent mechanism. Several cellular sources of ROS have been described (35) (36) (37) . Of these, NADPH oxidase is reportedly the major source of ROS in the vasculature (15) and has been consistently implicated in models of CVD (38) . This oxidase is a multimeric enzyme complex, consisting of membrane-associated (Nox homologs and p22 phox ) and cytosoplasmic (p47 phox homologs, p67 phox homologs, and rac) subunits (39) . Several variants of NADPH oxidase, expressed in a cell-and tissue-specific manner, have been reported (40) . Both Nox-1 and -4 are expressed in human and mouse ASMC (41, 42) . Studies implicate NADPH oxidases as TP effectors (16, 18) , although the particular isoform that couples with the TP has not been identified.
We used two pharmacological inhibitors of NADPH oxidases. DPI, a general inhibitor of flavoproteins, including NADPH oxidases, and apocynin, a nonselective NADPH oxidase inhibitor, virtually abolished IBOP-induced TP upregulation in TPa-HEK. Moreover, IBOP treatment did not initiate TP upregulation in ASMCs treated with apocynin or derived from mice genetically lacking the functionally critical p47 phox subunit. The internal consistency across the cell types, and between the pharmacological and genetic manipulations used, strongly implicates one or more NADPH oxidases in enhanced expression of the activated TP. We did not assess directly which NADPH oxidase isoform was involved. Indeed, given the consistent responses observed across different cells types, it is possible that more than one isozyme can subserve this function. However, since both apocynin and p47 phox deletion can inhibit the function of Nox1, but not Nox 4 (38) , the former enzyme is a likely candidate. Currently, we are characterizing the particular NADPH oxdiase subunits that are downstream of TPa and that direct regulation of its expression.
TP upregulation was also induced by the isoprostane iPE 2 III (Fig. 2C, D) . Isoprostanes are free radical-catalyzed products of arachidonic acid that activate the TP in vivo (26) . Like TxA 2 (43) , isoprostanes are elevated in syndromes of vascular disease and are thought to act as pro-atherogenic TP ligands (2, 3) . Isoprostane formation in vitro (16) and in vivo (44) occurs secondary to activation of the NADPH oxidase ROS-generating complex. Thus, TP-mediated NADPH oxidase activation may augment formation of isoprostanes, incidental TP agonists, and established biomarker of CVD, driving increased TP expression.
Homologous upregulation of TPa was not dependent on modulation of TPa transcription, suggesting a posttranscriptional mechanism. We examined changes in stability of the activated TP protein. The ER plays a crucial role in protein biosynthesis and quality control (45) . Proteins retained in the ER typically undergo rapid proteosomal degradation. Alternatively, proteins may proceed to the Golgi before localization of the mature protein in its appropriate cellular compartment (46) . Maturation of many GPCRs, including the TPa (27) , involves glycosylation as the receptors moves along this ER-Golgi biogenic pathway. By subcellular fractionation and immunofluoresence microscopy, we observed mobilization of the TPa from the ER to the Golgi following IBOP treatment, consistent with the concept that agonist activation drives TPa biogenesis.
Using cyclohexamide to inhibit protein biosynthesis, we previously demonstrated agonist-dependent degradation of TPa (20) . In this study, activation of the TPa with IBOP, prior to addition of cyclohexamide, allowed us to examine whether agonist activation altered TPa stability. We observed that TPa degradation was significantly offset in IBOP-pretreated cells, but not when DPI was added to the IBOP treatment, consistent with ROS-dependent receptor stabilization. Interestingly, stabilization was evident only for the immature (39 kDa) form of the TPa, which localized to the ER fraction (data not shown). Taken together with the observed cellular localization of agonist-activated TPa in the Golgi, these data suggest that ROS-mediated TPa stabilization occurs early in TPa generation, driving immature receptor into the ER-Golgi biogenic pathway. NADPH oxidase subunits are ER localized in both vascular SMCs (47) and endothelium (48) , placing this ROS-generating system in an appropriate cellular compartment for manipulation of ER-localized TP.
Under cyclohexamide-treated conditions, stabilization of immature TPa did not translate into a sustained elevation of mature receptor, perhaps because of simultaneous degradation of the mature receptor. Alternatively, the sensitivity of mature TP to cycloheximide in IBOP-pretreated cells may indicate that a chaperone, or other modifying protein, is required for trafficking of the TPa along its biogenic pathway. Indeed, several candidate mechanistic pathways for ROS-dependent upregulation of TPa expression exist. Exogenous H 2 O 2 increases expression of ER chaperone proteins, such as HSP70 (49) , and several members of the 14-3-3 family (50). Interestingly, 14-3-3z (51) is one of several reported TPa interacting proteins, along with RACK1 (52), Rab11 (53) , and peroxiredoxin-4 (54). Recently, a ROS signaling pathway was implicated in TPdependent activation of AMP-activated kinase in vascular SMCs (55) . The contribution of these potential mechanistic pathways to homologous ROS-dependent TPa upregulation is currently being explored.
Both TxA 2 (4, 56) and NADPH oxidases (57, 58) have an established role in atherogenesis and in the proliferative Fig. 9 . Role of ROS in homologous TP stabilization. Transiently transfected 3xHAhTPa2HEK were treated with vehicle or IBOP (100 nM) for 1 h in the absence or presence (hatched bars) of DPI (10 mM; 30 min pretreatment). Cells were then treated with (black bars or hatched bars) or without cyclohexamide (CHX; 50 mg/ml) for 6 h to unmask TP degradation. A: Representative Western blot. B and C show densitometric analysis of mature TP (B) and immature TP (C), normalized to b-actin. Fold change in IBOP-induced TP expression was calculated as the ratio of expression in IBOP-treated/ non-IBOP-treated cells, with all other treatments being identical. Data are mean 6 SEM (n 5 5). ns, nonsignificant. * P , 0.05 w.r.t. 1-fold (i.e., no effect).
response to vascular injury. This study demonstrates that signaling levels of ROS, derived from one or more NADPH oxidases, drive a novel pathway of TP upregulation. Thus, while the activated receptor is being internalized and degraded (20) , a distinct ROS-dependent feed-forward pathway drives enhanced receptor biogenesis to ultimately increase expression of functional TP. Activation of this feed-forward loop may underlie the augmented TP expression observed in CVD (6, 7) . In addition, oxidant-dependent mobilization of an intracellular TP reserve, via this novel mechanism, may explain the enhanced response to 8-iso-prostaglandin F 2a , another TP-dependent isoprostane (2), in oxidatively stressed isolated rat hearts (59) . Conceptually, this feedforward loop is highly relevant to CVD where the milieu of vasoactive mediators generated includes TxA 2 , isoprostanes, and other NADPH oxidase activators.
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